Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. Show more
- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data...
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val’s...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0038 | 2.52996005326 | 0.1502 | 0.164 | 0.1315 | 665779 | 0.15115673 | CS |
| 4 | -0.0869 | -36.0730593607 | 0.2409 | 0.2972 | 0.1315 | 2630534 | 0.21148833 | CS |
| 12 | -0.0622 | -28.7696577243 | 0.2162 | 0.2972 | 0.1315 | 1058434 | 0.21488975 | CS |
| 26 | -0.656 | -80.987654321 | 0.81 | 0.846 | 0.1315 | 777041 | 0.27780607 | CS |
| 52 | -0.4174 | -73.0486524326 | 0.5714 | 1.31 | 0.1315 | 458918 | 0.33567976 | CS |
| 156 | -5.136 | -97.0888468809 | 5.29 | 5.75 | 0.1315 | 274059 | 1.38295408 | CS |
| 260 | -16.606 | -99.0811455847 | 16.76 | 18.24 | 0.1315 | 274371 | 3.09447825 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
